Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19069165 | 0.82 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL24600765 | 0.82 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL12313634 | 0.80 | GMNN (0.33) | CA1CA2MGLL | |
| SCHEMBL9004338 | 0.77 | POLB (0.32) | POLB | |
| SCHEMBL24690695 | 0.76 | GMNN (0.30) | CA1CA2MGLL | |
| SCHEMBL21108564 | 0.73 | PTGS1 (0.34) | MGLL | |
| SCHEMBL21108746 | 0.72 | MGLL (0.37) | CA1CA2MGLL | |
| SCHEMBL122937 | 0.71 | — | — | |
| SCHEMBL19670782 | 0.71 | — | — | |
| SCHEMBL22420047 | 0.70 | MGLL (0.40) | CA1CA2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-20220213080-A1 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME | HUSCION CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | CA1 4107/4885CA2 3325/4885GSK3A 544/4885 |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CA1 2493/4885CA2 948/4885GSK3A 394/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CA1 3274/4885CA2 1972/4885GSK3A 1313/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | CA1 2493/4885CA2 948/4885GSK3A 394/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CA1 2177/4885CA2 1738/4885GSK3A 255/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | CA1 2061/4885CA2 2552/4885GSK3A 1561/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CA1 4107/4885CA2 3325/4885GSK3A 544/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CA1 3274/4885CA2 1972/4885GSK3A 1313/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CA1 3888/4885CA2 3859/4885GSK3A 1298/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CA1 4107/4885CA2 3325/4885GSK3A 544/4885 |
| US-20220213080-A1 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME | NFATC1, IRF2BP2, IKBKG | CA1 4710/4885CA2 3917/4885GSK3A 4677/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CA1 4107/4885CA2 3325/4885GSK3A 544/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | CA1 2009/4885CA2 701/4885GSK3A 3819/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CA1 3274/4885CA2 1972/4885GSK3A 1313/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CA1 3888/4885CA2 3859/4885GSK3A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.